Cargando…

Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity

COVID-19, caused by SARS-CoV-2, is characterized by pneumonia, lymphopenia, exhausted lymphocytes and a cytokine storm. Several reports from around the world have identified obesity and severe obesity as one of the strongest risk factors for COVID-19 hospitalization and mechanical ventilation. Moreo...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasquarelli-do-Nascimento, Gabriel, Braz-de-Melo, Heloísa Antoniella, Faria, Sara Socorro, Santos, Igor de Oliveira, Kobinger, Gary P., Magalhães, Kelly Grace
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399077/
https://www.ncbi.nlm.nih.gov/pubmed/32849309
http://dx.doi.org/10.3389/fendo.2020.00530
_version_ 1783566078511677440
author Pasquarelli-do-Nascimento, Gabriel
Braz-de-Melo, Heloísa Antoniella
Faria, Sara Socorro
Santos, Igor de Oliveira
Kobinger, Gary P.
Magalhães, Kelly Grace
author_facet Pasquarelli-do-Nascimento, Gabriel
Braz-de-Melo, Heloísa Antoniella
Faria, Sara Socorro
Santos, Igor de Oliveira
Kobinger, Gary P.
Magalhães, Kelly Grace
author_sort Pasquarelli-do-Nascimento, Gabriel
collection PubMed
description COVID-19, caused by SARS-CoV-2, is characterized by pneumonia, lymphopenia, exhausted lymphocytes and a cytokine storm. Several reports from around the world have identified obesity and severe obesity as one of the strongest risk factors for COVID-19 hospitalization and mechanical ventilation. Moreover, countries with greater obesity prevalence have a higher morbidity and mortality risk of developing serious outcomes from COVID-19. The understanding of how this increased susceptibility of the people with obesity to develop severe forms of the SARS-CoV-2 infection occurs is crucial for implementing appropriate public health and therapeutic strategies to avoid COVID-19 severe symptoms and complications in people living with obesity. We hypothesize here that increased ACE2 expression in adipose tissue displayed by people with obesity may increase SARS-CoV-2 infection and accessibility to this tissue. Individuals with obesity have increased white adipose tissue, which may act as a reservoir for a more extensive viral spread with increased shedding, immune activation and pro-inflammatory cytokine amplification. Here we discuss how obesity is related to a pro-inflammatory and metabolic dysregulation, increased SARS-CoV-2 host cell entry in adipose tissue and induction of hypercoagulopathy, leading people with obesity to develop severe forms of COVID-19 and also death. Taken together, it may be crucial to better explore the role of visceral adipose tissue in the inflammatory response to SARS-CoV-2 infection and investigate the potential therapeutic effect of using specific target anti-inflammatories (canakinumab or anakinra for IL-1β inhibition; anti-IL-6 antibodies for IL-6 inhibition), anticoagulant or anti-diabetic drugs in COVID-19 treatment of people with obesity. Defining the immunopathological changes in COVID-19 patients with obesity can provide prominent targets for drug discovery and clinical management improvement.
format Online
Article
Text
id pubmed-7399077
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73990772020-08-25 Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity Pasquarelli-do-Nascimento, Gabriel Braz-de-Melo, Heloísa Antoniella Faria, Sara Socorro Santos, Igor de Oliveira Kobinger, Gary P. Magalhães, Kelly Grace Front Endocrinol (Lausanne) Endocrinology COVID-19, caused by SARS-CoV-2, is characterized by pneumonia, lymphopenia, exhausted lymphocytes and a cytokine storm. Several reports from around the world have identified obesity and severe obesity as one of the strongest risk factors for COVID-19 hospitalization and mechanical ventilation. Moreover, countries with greater obesity prevalence have a higher morbidity and mortality risk of developing serious outcomes from COVID-19. The understanding of how this increased susceptibility of the people with obesity to develop severe forms of the SARS-CoV-2 infection occurs is crucial for implementing appropriate public health and therapeutic strategies to avoid COVID-19 severe symptoms and complications in people living with obesity. We hypothesize here that increased ACE2 expression in adipose tissue displayed by people with obesity may increase SARS-CoV-2 infection and accessibility to this tissue. Individuals with obesity have increased white adipose tissue, which may act as a reservoir for a more extensive viral spread with increased shedding, immune activation and pro-inflammatory cytokine amplification. Here we discuss how obesity is related to a pro-inflammatory and metabolic dysregulation, increased SARS-CoV-2 host cell entry in adipose tissue and induction of hypercoagulopathy, leading people with obesity to develop severe forms of COVID-19 and also death. Taken together, it may be crucial to better explore the role of visceral adipose tissue in the inflammatory response to SARS-CoV-2 infection and investigate the potential therapeutic effect of using specific target anti-inflammatories (canakinumab or anakinra for IL-1β inhibition; anti-IL-6 antibodies for IL-6 inhibition), anticoagulant or anti-diabetic drugs in COVID-19 treatment of people with obesity. Defining the immunopathological changes in COVID-19 patients with obesity can provide prominent targets for drug discovery and clinical management improvement. Frontiers Media S.A. 2020-07-28 /pmc/articles/PMC7399077/ /pubmed/32849309 http://dx.doi.org/10.3389/fendo.2020.00530 Text en Copyright © 2020 Pasquarelli-do-Nascimento, Braz-de-Melo, Faria, Santos, Kobinger and Magalhães. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Pasquarelli-do-Nascimento, Gabriel
Braz-de-Melo, Heloísa Antoniella
Faria, Sara Socorro
Santos, Igor de Oliveira
Kobinger, Gary P.
Magalhães, Kelly Grace
Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity
title Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity
title_full Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity
title_fullStr Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity
title_full_unstemmed Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity
title_short Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity
title_sort hypercoagulopathy and adipose tissue exacerbated inflammation may explain higher mortality in covid-19 patients with obesity
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399077/
https://www.ncbi.nlm.nih.gov/pubmed/32849309
http://dx.doi.org/10.3389/fendo.2020.00530
work_keys_str_mv AT pasquarellidonascimentogabriel hypercoagulopathyandadiposetissueexacerbatedinflammationmayexplainhighermortalityincovid19patientswithobesity
AT brazdemeloheloisaantoniella hypercoagulopathyandadiposetissueexacerbatedinflammationmayexplainhighermortalityincovid19patientswithobesity
AT fariasarasocorro hypercoagulopathyandadiposetissueexacerbatedinflammationmayexplainhighermortalityincovid19patientswithobesity
AT santosigordeoliveira hypercoagulopathyandadiposetissueexacerbatedinflammationmayexplainhighermortalityincovid19patientswithobesity
AT kobingergaryp hypercoagulopathyandadiposetissueexacerbatedinflammationmayexplainhighermortalityincovid19patientswithobesity
AT magalhaeskellygrace hypercoagulopathyandadiposetissueexacerbatedinflammationmayexplainhighermortalityincovid19patientswithobesity